SOURCE: Atossa Genetics, Inc.

Atossa Genetics, Inc.

November 10, 2016 08:15 ET

Atossa Genetics to Provide Company Update and Discuss Third Quarter 2016 Financial Results on Conference Call on Monday, November 14, 2016

SEATTLE, WA--(Marketwired - Nov 10, 2016) - Atossa Genetics, Inc. (NASDAQ: ATOS) announced today that it will provide a Company update and discuss third quarter 2016 financial results on Monday, November 14, 2016 at 5:30 pm eastern time. Following management's formal remarks, there will be a question and answer session.

To listen to the call by phone, interested parties within the U.S. should call 1-844-824-3830 and International callers should call 1-412-317-5140. All callers should ask for the Atossa Genetics conference call. The conference call will also be available through a live webcast at www.atossagenetics.com. Details for the webcast may be found on the Company's IR events page at http://ir.atossagenetics.com/ir-calendar.

A replay of the call will be available approximately one hour after the end of the call through December 14, 2016. The replay can be accessed via Atossa's website or by dialing 877-344-7529 (domestic) or 412-317-0088 (international) or Canada Toll Free at 855-669-9658. The replay conference ID number is 10096671.

About Atossa Genetics
Atossa Genetics, Inc. is a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions. For more information, please visit www.atossagenetics.com.

Forward-Looking Statements
Forward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa, lower than anticipated rate of patient enrollment, results of clinical studies, the safety and efficacy of Atossa's products and services, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others with respect to fulvestrant, such as patent rights, and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.

Contact Information

  • Atossa Genetics Company Contact:
    Atossa Genetics, Inc.
    Kyle Guse
    CFO and General Counsel
    (O) 800-351-3902
    kyle.guse@atossagenetics.com

    Investor Relations Contact
    Scott Gordon
    CorProminence LLC
    377 Oak Street
    Concourse 2
    Garden City, NY 11530
    Office: 516.222.2560
    scottg@corprominence.com